Crizotinib is used worldwide for the treatment of ALK-positive NSCLC; however, there is increasing accumulation of data with regard to its potential adverse events, which may be severe. Additionally, HGF is reportedly produced by bone marrow stromal cells and plays a role in promoting hematopoiesis via the c-Met receptor [ 9 ]. The duration of crizotinib treatment in our case is superior to the median progression-free survival of 7. In this case, the patient exhibited an eminently prolonged response to pemetrexed, which preceded crizotinib treatment. Furthermore, this clinical trial confirmed that the incidence of severe neutropenia was higher in the high-dose group than in the low-dose group. Although crizotinib was associated with potentially fatal pneumonitis or interstitial lung disease ILD in a few number of patients [ 26 , 27 ], such events may be related to NSCLC or previous treatment such as radiotherapy rather than to crizotinib [ 34 ].
Introduction Non-small-cell lung cancer NSCLC is the most commonly diagnosed type of cancer and is a leading cause of cancer-related mortality worldwide 1. In the present case, however, neutropenia first developed at 8 weeks and was not observed with rechallenge by dose-reduction of crizotinib. Median duration of response was Currently, strategies aiming to maximize treatment benefit for NSCLC are centered on individualized treatments based on the molecular profile of the disease. The duration of crizotinib treatment in our case is superior to the median progression-free survival of 7. The discovery of hepatocyte growth factor HGF and its significance for cell biology, life sciences and clinical medicine. Median PFS was significantly higher with crizotinib
Subsequently, crizotinib therapy was initiated.
Support Center Support Center. Published online Jan Active EGFR mutations were not identified.
Identifying markers of immune response in ovarian cancer: In this case, the patient exhibited an eminently prolonged response to pemetrexed, which preceded crizotinib treatment. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. Data are available from patients enrolled and treated up to Februaryof whom were evaluable for response.
XALKORI case study | TIGCRU Insight
The identification of mutations of the epidermal growth factor receptor EGFR gene and development of its tyrosine kinase inhibitors have signifficantly affected the potency of the response to NSCLC treatment and has led to additional oncogenic drivers being aggressively investigated.
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Patients whose tumours express ALK fusion proteins are eligible for treatment with ALK inhibitors, the first of which was crizotinib.
Targeted therapy in non-small-cell lung cancer – is it becoming a reality?
XALKORI case study
Crizotinib should, however, be discontinued if treatment-related pneumonitis occurs and standard treatments for ILD should be considered [ 34 ].
Oxford University Press is a department xxalkori the University of Oxford. Xalkori adverse drug reactions reported from the post-marketing surveillance in Japan. Relapse was experienced following third-line chemotherapy with pemetrexed and anaplastic lymphoma kinase ALK -positive adenocarcinoma was diagnosed using a specimen from the resected ovarian tumor.
This patient was treated with crizotinib for 71 weeks cse In the present case, crizotinib treatment was re-initiated following a brief interruption and the initiation of PPI therapy.
Survival benefit of pemetrexed in lung adenocarcinoma patients with anaplastic lymphoma kinase gene rearrangements. However, 1 year after the start of clinical trials, ALK was recognised as a molecular target in NSCLC [ 71116 ] and shortly afterwards a diagnostic assay was developed to casee for ALK -positive patients [ 16 ], allowing crizotinib to be evaluated in this population.
For permissions, please email: Therefore, this disease may be diagnosed using previously obtained samples.
As a result, there is an unmet clinical need in advanced NSCLC, with potential to improve outcomes by identifying distinct molecular subtypes of patients who may respond to specific targeted therapies.
Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase ALK gene rearrangement, is generally well tolerated. Median duration of response was Whole-body computed tomography CT revealed multiple nodular shadows in the left pulmonary field, a left pleural effusion and a multi-locular tumor in the right ovary Fig. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer — clinical results and biomarker analysis of GeparNuevo study.
In such cases, interruption and dose reduction of crizotinib might be necessary for some patients with severe neutropenia. Successful treatment with stury after crizotinib-induced esophageal ulceration.
A year-old woman was admitted to our hospital with a left pleural effusion. In line with this, it can be presumed that the inhibitory action of crizotinib against the c-Met receptor might induce neutropenia in a dose-dependent manner. Several studies have confirmed that alectinib is an effective alternative in patients for whom crizotinib has been discontinued because of serious AEs such as dysgeusia and esophageal ulceration [ 1314 ].
Thus, we conclude that the pathogenesis of neutropenia in the present case might be associated with the inhibitory action against the c-Met receptor rather than an immune-mediated reaction.